ASF GROUP LIMITED — Capital/Financing Update 2019

Aug 12, 2019

==> picture [122 x 38] intentionally omitted <==

ASF GROUP LIMITED

ACN 008 924 570 Bennelong, 2/3B Macquarie Street Sydney NSW 2000 Telephone: (61 2) 9251 9088 Facsimile: (61 2) 9251 9066 www.asfgroupltd.com

13 August 2019

The Manager Company Announcements Australian Securities Exchange 20 Bridge Street Sydney NSW 2000 via: www.asxonline.com

Dear Sir/Madam

ASF Biotech Investment in the UK

ASF Group Limited (ASX:AFA) is pleased to advise that it has invested into an exciting new biotech opportunity being commercialised from intellectual property (“ IP ”) developed by Prof. Che Connon from Newcastle University, UK.

The ground-breaking biotech IP won the 2018 London Medical Design Gold Award and comprise a method wherein stem cell derived corneal collagen production via 3D printed constructs create improved corneal function in human cornea transplants.

The investors including Newcastle University, Prof. Connon, and ASF will form a company to be called 3D Bio-Tissues Ltd. (“ 3DBT ”) for In Vivo Phases & animal trials of the IP. ASF is investing into 3DBT over time to take its investment up to 49% equity interest.

We will keep the market informed of developments in due course.

Information about ASF

ASF Group Limited (ASX: AFA) is unique among ASX-listed public companies as it powers business between the East and West. ASF is an investment and trading house which focuses principally on the identification, incubation and realization of opportunities in areas of synergy between China, Australia, UK and Europe including technology, oil & gas, resources, property, infrastructure, travel and financial services sectors.

Geoff Baker Director ASF Group Ltd Ph: +612 9251 9088